|
Synonyms: garetosmab-grts | Pasatru® | REGN-2477 | REGN2477
garetosmab is an approved drug
Compound class:
Antibody
Comment: Garetosmab (REGN2477) is a fully human anti-activin A (INHBA) monoclonal antibody [4]. The antibody blocks signaling of activins containing the inhibin βα subunit (i.e., activins A, AB, and AC). Peptide sequence matches in a patent search suggests that garetosmab is antibody H4H10446P2 in Regeneron Pharmaceuticals' patent US9718881B2 [3].
|
| No information available. |
Summary of Clinical Use ![]() |
| Garetosmab (REGN2477) was progressed as a clinical candidate for the treatment of fibrodysplasia ossificans progressiva (FOP) [1]. First approval was granted by the US FDA in August 2026, to reduce new heterotopic ossification and flare-ups in patients with FOP. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT05394116 | A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP) | Phase 3 Interventional | Regeneron Pharmaceuticals | ||
| NCT07559513 | A Study to Investigate the Safety, Pharmacokinetics (PK), and Efficacy of Garetosmab in Children and Adolescents With Fibrodysplasia Ossificans Progressiva (FOP) | Phase 3 Interventional | Regeneron Pharmaceuticals | ||
| NCT03188666 | A Study to Examine the Safety, Tolerability and Effects on Abnormal Bone Formation of REGN2477 in Patients With Fibrodysplasia Ossificans Progressiva | Phase 2 Interventional | Regeneron Pharmaceuticals | 2 | |